La cadena de opciones muestra datos clave de las opciones de acciones de Genprex a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Genprex..

Genprex (NASDAQ:GNPX) Bolsa, Cadena de Opciones

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

ACLS

AMKR

BHAT

BNAI

FLNC

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

Genprex Inc

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Merck, Black Hills, and Virtus Investment Partners have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 4-6%.
Merck
Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) is a healthcare company that manufactures pharmaceutical products to treat various conditions in many therapeutic areas, including cardiometabolic disease, cancer and infections.&nbsp;
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Merck has raised its dividends every year for the last 14 years. According to its most recent dividend hike announcement on Nov. 19, the company increased the quarterly payout from $0.77 to $0.81 per share, equal to an annual figure of $3.24 per share. The current dividend yield on the stock is 4.09%.&nbsp;
Merck&#8217;s annual revenue as of Dec. 31 stood at $64.17 billion. In its Q4 2024 earnings report on Feb. 4, it posted revenues of $15.62 billion and EPS of $1.72. Both figures beat the Street estimates.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Black Hills
Black Hills Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) operates as an electric and natural gas utility company in the U.S.&nbsp;
Black Hills has raised its dividends every year for the last 55 years. In its most recent dividend hike announcement on Jan. 24, it increased the quarterly payout from $0.65 to $0.676 per share, which is equal to an annual figure of $2.70 per share. Currently, the dividend yield on the stock is 4.63%.
Black Hills&#8217; annual revenue as of Dec. 31 stood at $2.13 billion. As per the company&#8217;s Q4 2024 earnings release on Feb. 5, it posted revenues of $597.10 million, missing the consensus of $944 million, while EPS of $1.37 came in above the consensus estimate of $1.34.
How to put $100 in your retirement fund each month with Black Hills stock? Check out this <a href="https://www.benzinga.com/markets/25/01/43313814/how-to-put-100-in-your-retirement-fund-each-month-with-black-hills-stock">article by Benzinga</a> to learn more.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Virtus Investment Partners
Virtus Investment Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients.&nbsp;
Virtus has raised its dividends consecutively for the past seven years. In its most recent dividend hike announcement on Aug. 15, the company's board increased its quarterly payout by 18% to $2.25 per share, which is equal to $9 per share annually. More recently, in its dividend announcement on Feb. 27, the company maintained the payout at the same level. The current dividend yield on the stock is 5.95%.
Its annual revenue as of Dec. 31 stood at $902.82 million. In its most recent earnings release on Jan. 31, the company posted Q4 2024 revenues of $233.49 million and EPS of $7.50. Both figures came in above the consensus estimates.
Merck, Black Hills, and Virtus Investment Partners are good choices for investors seeking reliable passive income. Their dividend yields of around 4-6% and long history of consistent hikes make them attractive to income-focused investors.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44778984/why-regency-centers-cme-group-and-trinity-industries-are-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

VRTS

Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income

It's not something most people expect to find while cleaning out a loved one's home, but it happens. One listener of the "<a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-revisiting-can-i-give-my-child-money-and-get-a-tax-deduction">Women &amp; Money</a>" podcast recently asked financial expert Suze Orman what to do after discovering $200,000 in cash stashed away by her deceased father.
The listener explained that her father didn't trust banks and saved his paychecks in cash, hiding them around the house over time. Now, she's faced with a major question: What's the right way to handle this money?
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Here's how Suze Orman responded.
<h2 class="wp-block-heading">Step 1: Don't Let the Money Sit in Cash</h2>
Orman began by stressing the opportunity cost of keeping such a large sum in cash. "You're missing out on about $10,000 a year currently in interest," she noted.
Letting the money sit at home not only limits its earning potential — it also puts it at risk of theft or loss. That's why <a href="https://www.benzinga.com/personal-finance/25/03/44424162/its-a-really-really-bad-idea-suze-orman-warns-58-year-old-against-using-a-401k-to-buy-a-lifetime">Orman</a> believes the safest next step involves depositing it. But that's not as simple as walking into a bank with stacks of cash.
<h2 class="wp-block-heading">Step 2: Talk to the Estate Lawyer</h2>
Before heading to the bank, Orman recommends contacting the attorney handling the estate. If there's no lawyer involved, she advises hiring one, even for a short consultation. They can guide you on how to legally deposit the money and ensure everything is above board.
Why the caution? Large deposits — especially over $10,000 — trigger federal reporting requirements. Banks are required to report these transactions to government agencies as part of <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42266678/coinbase-ceo-brian-armstrong-failed-anti-money-laundering-regulations-sounds-like-a-job-for-doge">anti-money-laundering rules</a>.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">Step 3: Be Transparent With the Bank</h2>
Orman suggests going to a bank where either you or your loved one had an account. Bring documentation like the death certificate, the will or trust, and any paperwork that shows you're the <a href="https://www.benzinga.com/personal-finance/25/01/42803339/keep-it-separate-suze-orman-warns-listener-about-protecting-her-childrens-inheritance-when-buying-a-home-with-a-new-spouse">beneficiary of the estate</a>.
"Just come clean," she advises. Explain how and where the money was found, and that you're trying to handle it responsibly. The bank may have questions, but full transparency can help avoid future issues.
<h2 class="wp-block-heading">Step 4: Deposit the Money Into the Estate Account</h2>
Rather than depositing the funds directly into your personal account, Orman recommends opening a bank account in the name of the estate. This keeps everything tied to the deceased person's financial affairs and can simplify the probate process, if applicable.
Once the cash is deposited into the estate account, it becomes part of the official estate assets. From there, you or the executor can distribute it according to the terms of the will or trust — or as directed by the probate court.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Taxes Could Be Involved</h2>
Orman also cautioned that depending on your situation, the IRS might treat the money as part of the estate and expect a portion in taxes. Or, they might accept your explanation and move on. Either way, working with a lawyer and possibly a tax professional can help ensure you follow the right steps.
If you find a large sum of cash in a loved one's home, don't panic — but don't ignore it either. Follow Orman's lead: seek legal guidance, stay transparent, and take the right steps to protect yourself and the money.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

What Would You Do If You Found $200,000 Cash In A Deceased Loved One's Home? Here's What Suze Orman Would Do

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.83% on an annualized basis producing an average annual return of 14.73%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $108.47 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 20 years ago, it would be worth $1,560.78 today based on a price of $220.07 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745019912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 291.15% on an annualized basis producing an average annual return of 305.18%. Currently, Quest Diagnostics has a market capitalization of $18.18 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $963,529.41 today based on a price of $163.80 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745019021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 18.21% on an annualized basis producing an average annual return of 26.1%. Currently, Intuitive Surgical has a market capitalization of $172.95 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 20 years ago, it would be worth $9,987.72 today based on a price of $482.74 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745018120_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

One Reddit user just gave the economy subreddit a glimpse into what panic looks like in real time.
In the popular r/Economy <a href="https://www.reddit.com/r/economy/comments/1jyig4s/ok_i_sold_all_of_my_holdings_and_am_100_cash/">subreddit</a>, the user said they sold all of their holdings and are &#8220;100% cash until 2026 midterms because this administration is full of 6-year-olds.&#8221;
They added, &#8220;All of my personal investments have turned into 100% cash and sold when the market was very low (I'm still kicking myself in the ass everyday for doing that).&#8221;
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
<h2 class="wp-block-heading">Market Timing vs. Market Patience</h2>
Despite the regret, they said they couldn't handle the volatility anymore, even though they were invested in a broadly diversified fund: &#8220;I feel like I'm day trading Vanguard Total Stock ETF. It's just so horrendous.&#8221;
Reactions flooded in, and the general consensus was that selling low and holding cash isn't the win the user might think it is.
&#8220;You want to buy more when the market is down, not sell,&#8221; one user said.
Another pointed out the trap of market timing: &#8220;If you think you timed the top, now you gotta time the bottom. Probably gonna get mad if the market goes up.&#8221;
Several commenters also noted how common this mistake is, especially among younger investors. &#8220;Selling in 2009 is my greatest regret,&#8221; one user shared. &#8220;The best buying opportunities always look the most awful and scary.&#8221;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">Cash Isn&#8217;t as Safe as It Feels</h2>
While the original poster parked their money in a high-yield savings account, multiple users reminded them that cash isn't immune to erosion.
&#8220;The dollar <a href="https://www.benzinga.com/markets/equities/25/04/44768702/foreigners-dump-the-dollar-gold-and-yen-act-as-safe-haven-jpmorgan-helps-stock-market-cooler-ppi">isn&#8217;t safe</a> right now,&#8221; one comment read. &#8220;You&#8217;re protected against market volatility but <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44764554/consumer-sentiment-crashes-to-3-year-lows-as-inflation-expectations-spike-to-1981-highs">inflation</a> is going to make your cash worth less than other, more safe investment choices.&#8221;
A few recommended alternatives like <a href="https://www.benzinga.com/news/treasuries/25/04/44774759/from-boring-to-booming-how-treasury-etfs-are-beating-the-bear">Treasury ETFs</a>, <a href="https://www.benzinga.com/money/best-cd-rates">CDs</a>, <a href="https://www.benzinga.com/25/03/44259396/short-term-bond-etfs-see-record-inflows-amid-market-turmoil-3-funds-that-led-the-surge">short-term investment grade bonds</a> and even <a href="https://www.benzinga.com/25/04/44652150/sit-out-market-drama-with-these-3-dividend-funds">dividend-focused ETFs</a>.
&#8220;Money Market or cash/dividends ETF. Inflation is still up which means returns on cash accounts with interest given are currently a relatively safe place to park money,&#8221; one user wrote.
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Politics, Tariffs and Uncertainty</h2>
Politics were central to the original post, and the comment section didn't shy away either.
Many mentioned President Donald Trump's tariff policies and their ripple effects on markets. One user explained, &#8220;[Trump] <a href="https://www.benzinga.com/news/25/04/44779286/trumps-tariff-pause-stirs-markets-goldman-sachs-reverses-recession-call-and-more-this-week-in-economy">paused tariffs for 90 days</a> to all the countries (except China) who were selling US bonds on the open market, causing the interest rates to rise.&#8221;
Another summed up the frustration with policy-driven volatility: &#8220;Markets dislike uncertainty. As you can see from these comments, certainty is in short supply. Nobody knows. Do your best.&#8221;
Some took it further, blaming both sides of the aisle. &#8220;This isn't going to be a quick recession like COVID. We have a few problems we have to unwind and I'm pessimistic there is anyone capable of leading us out of this, Republicans or Democrats. It's scary out there.&#8221;
See Also: With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.
<h2 class="wp-block-heading">So Was It a Bad Move?</h2>
Most think so. &#8220;If you hadn&#8217;t sold you would have lost nothing,&#8221; one said. &#8220;Investing by your politics is foolish.&#8221;
Others were more empathetic. &#8220;There is no wrong move if it gives you peace of mind,&#8221; a top commenter added. &#8220;You might miss out on some gains. That's irrelevant if the stress and potential losses can alter your life plans.&#8221;
Still, the original poster might be left with the worst of both worlds: locking in losses from selling low and watching inflation chip away at their savings.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>
Image: Shutterstock

'This Administration Is Full Of 6-Year-Olds'—Investor Says They 'Sold All Of Their Holdings' And Is '100% Cash Until The 2026 Midterms'

OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 14.24%. Currently, OSI Systems has a market capitalization of $3.26 billion. 
Buying $100 In OSIS: If an investor had bought $100 of OSIS stock 15 years ago, it would be worth $647.95 today based on a price of $194.19 for OSIS at the time of writing.
<h3>OSI Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745017216_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OSIS

Here's How Much $100 Invested In OSI Systems 15 Years Ago Would Be Worth Today

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) has outperformed the market over the past 15 years by 2.18% on an annualized basis producing an average annual return of 12.45%. Currently, Fastenal has a market capitalization of $46.88 billion. 
Buying $1000 In FAST: If an investor had bought $1000 of FAST stock 15 years ago, it would be worth $5,806.41 today based on a price of $81.73 for FAST at the time of writing.
<h3>Fastenal's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745016311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FAST

Here's How Much You Would Have Made Owning Fastenal Stock In The Last 15 Years

Elon Musk is the <a href="https://www.benzinga.com/startups/25/01/43101102/elon-musk-the-richest-man-in-the-world-is-estimated-to-earn-over-23-million-every-single-hour-of-the-day-heres-how-hes-spending-it">richest man in the world</a>. Not marginally — dramatically. Even 1% of his net worth is more than most people could spend in multiple lifetimes.
But in a 2022 post on X, Musk pushed back on the idea that Tesla operates like a traditional hierarchy.
"Everyone eats same food, uses same restrooms, etc — no executive chef or other ivory tower stuff," he wrote. "There shouldn't be this workers vs management two-class system. Everyone is a worker."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Everyone eats same food, uses same restrooms, etc – no executive chef or other ivory tower stuff. There shouldn't be this workers vs management two-class system. Everyone is a worker.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1532403096680288256?ref_src=twsrc%5Etfw">June 2, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Invest in the future of digital engagement: <a href="https://www.benzinga.com/money/vatom-adv">Own a piece of the $100 billion Metaverse for just $500</a>.</li>
</ul>
Now in 2025, and Musk is still fighting to reinstate a $56 billion Tesla compensation package that was struck down last year by a Delaware court.&nbsp;
The court's decision was grounded in findings that the package was negotiated by directors lacking independence from Musk and that shareholders were misled by flawed disclosures during the approval process. Chancellor Kathaleen McCormick described the <a href="https://www.reuters.com/legal/judge-rules-favor-plaintiffs-challenging-musks-tesla-pay-package-2024-01-30/">compensation as an "unfathomable sum"</a> and highlighted the undue influence Musk had over the board, noting close personal ties with several directors .
Meanwhile, factory workers at Tesla's plants in Texas and Nevada are reportedly earning as little as $22 an hour. Even at the top of the pay scale, hourly wages max out around $39, <a href="https://www.businessinsider.com/how-much-tesla-factory-workers-paid-per-hour-us">Business Insider</a> reported last year.&nbsp;
Trending: With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.
According to Tesla's proxy statement, Musk appeared to take home nothing in 2022—at least on paper. The company reported his total compensation as zero for the year, which technically brought the CEO-to-median-worker pay ratio down to 0:1.&nbsp;
But that snapshot doesn't tell the whole story. Just one year earlier, in 2021, Musk exercised a massive batch of stock options that were set to expire, realizing gains of $23.45 billion. <a href="https://www.sec.gov/Archives/edgar/data/1318605/000156459022024064/tsla-def14a_20220804.htm?utm_source=chatgpt.com">Tesla's filings show</a> his "total realized compensation" for 2021 was $734,762,107, and based on the median employee salary of around $40,000 that year, the pay ratio came out to 18,043 to 1.&nbsp;
Musk's supporters argue that his compensation was performance-based and tied to milestones that drove massive value for shareholders. Critics point out that while Tesla's valuation soared, the workers powering its growth haven't seen the same rewards — and in some cases, have even seen wages reduced.
The legal battle over Musk's record-breaking pay is ongoing. But so is the conversation about whether <a href="https://www.benzinga.com/markets/25/04/44778739/elon-musks-political-fallout-fuels-record-dump-of-used-tesla-cars-now-selling-for-thousands-below-market-value">Tesla really operates</a> without a two-class system — or whether that idea only works in theory, not on the assembly line.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>
Image: Shutterstock

Elon Musk Fights For 'Unfathomable' $56 Billion Tesla Payday As Factory Workers Earn $22/Hour — But Says: 'There Shouldn't Be a Two-Class System'

T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) has outperformed the market over the past 10 years by 12.93% on an annualized basis producing an average annual return of 22.5%. Currently, T-Mobile US has a market capitalization of $298.75 billion. 
Buying $1000 In TMUS: If an investor had bought $1000 of TMUS stock 10 years ago, it would be worth $7,686.71 today based on a price of $261.66 for TMUS at the time of writing.
<h3>T-Mobile US's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745015415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMUS

$1000 Invested In T-Mobile US 10 Years Ago Would Be Worth This Much Today

In the current market session, Norfolk Southern Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) price is at $219.84, after a 2.71% spike. However, over the past month, the stock fell by 5.14%, and in the past year, by 10.13%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745013621_0.png" alt="Past Year Chart" />

<h3>Norfolk Southern P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 33.44 in the Ground Transportation industry, Norfolk Southern Inc. has a lower P/E ratio of 18.5. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745013621_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Norfolk Southern

Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) has outperformed the market over the past 5 years by 12.68% on an annualized basis producing an average annual return of 26.71%. Currently, Raymond James Finl has a market capitalization of $27.35 billion. 
Buying $100 In RJF: If an investor had bought $100 of RJF stock 5 years ago, it would be worth $321.02 today based on a price of $133.46 for RJF at the time of writing.
<h3>Raymond James Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745013613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Raymond James Finl 5 Years Ago Would Be Worth Today

Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) has outperformed the market over the past 10 years by 6.34% on an annualized basis producing an average annual return of 15.91%. Currently, Tyler Technologies has a market capitalization of $24.72 billion. 
Buying $1000 In TYL: If an investor had bought $1000 of TYL stock 10 years ago, it would be worth $4,468.65 today based on a price of $573.50 for TYL at the time of writing.
<h3>Tyler Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745011811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) has outperformed the market over the past 5 years by 19.85% on an annualized basis producing an average annual return of 33.88%. Currently, Parker Hannifin has a market capitalization of $72.24 billion. 
Buying $1000 In PH: If an investor had bought $1000 of PH stock 5 years ago, it would be worth $4,175.04 today based on a price of $561.00 for PH at the time of writing.
<h3>Parker Hannifin's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745010916_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Parker Hannifin Stock In The Last 5 Years

In the current session, Synopsys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) is trading at $415.50, after a 0.04% drop. Over the past month, the stock fell by 7.86%, and in the past year, by 19.82%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1745010019_0.png" alt="Past Year Chart" />

<h3>How Does Synopsys P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 381.69 in the Software industry, Synopsys Inc. has a lower P/E ratio of 49.96. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745010019_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

SNPS

Price Over Earnings Overview: Synopsys

AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) has outperformed the market over the past 15 years by 3.53% on an annualized basis producing an average annual return of 13.81%. Currently, AerCap Holdings has a market capitalization of $18.48 billion. 
Buying $100 In AER: If an investor had bought $100 of AER stock 15 years ago, it would be worth $704.41 today based on a price of $97.38 for AER at the time of writing.
<h3>AerCap Holdings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745010014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning AerCap Holdings Stock In The Last 15 Years

GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) has outperformed the market over the past 20 years by 3.54% on an annualized basis producing an average annual return of 11.43%. Currently, GameStop has a market capitalization of $12.19 billion. 
Buying $1000 In GME: If an investor had bought $1000 of GME stock 20 years ago, it would be worth $8,794.75 today based on a price of $27.27 for GME at the time of writing.
<h3>GameStop's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745009116_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Ask 10 people what it takes to be <a href="https://www.benzinga.com/25/03/44131089/kevin-oleary-says-making-1-million-is-almost-impossible-but-getting-to-5-million-is-surprisingly-easier">financially set for life</a>, and most will throw out numbers with lots of commas: $5 million, $10 million, maybe more if they're feeling pessimistic about inflation and avocado prices. But Kevin O'Leary, entrepreneur and "Shark Tank" mainstay, says the real magic number isn't in the millions. It's $500,000.
In a <a href="https://youtube.com/shorts/TcpVd9VmE7M?si=oahf9HaAfL1BgPEU">2023 YouTube short</a>, O'Leary tackled the question head-on: How much do you need to live a comfortable or wealthy life? His answer? That depends on your lifestyle. But for many people, he says, half a million bucks in the bank can do the trick.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
"It's all about lifestyle," he says in the clip. "You can live off half a million bucks in the bank and do nothing else to make money."
Sounds too good to be true? It depends on what you do with that money and more importantly, what you don't do with it.
O'Leary explains if you're investing wisely, you could reasonably earn around 5% annually in fixed income with "very little risk." That's $25,000 a year without touching your principal — enough to cover modest living expenses, especially if you own your home and live in a low-cost area. Want to push that income a little higher? According to O'Leary, you could aim for 8.5% to 9% returns by mixing in equities, if you're willing to "ride the volatility."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
That added risk comes with potential reward but also potential stress. The market doesn't always cooperate, and while equities historically trend upward, there's no guarantee they'll behave when you need them to. If the idea of watching your <a href="https://www.benzinga.com/personal-finance/25/03/44316684/warren-buffett-said-bad-news-is-an-investors-best-friend-and-if-youre-not-ready-for-stocks-to-drop-50-you-shouldnt-be-investing">portfolio dip during a downturn</a> sends your blood pressure soaring, you might want to stick with the slower but steadier option.
But O'Leary isn't just handing out ideas — he's got strong feelings about what not to do.
"Do not invest in your brother's restaurant or a bowling alley or a bar," he warns. "Or all that other crap. You'll lose your money on that."
Point taken.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Still, his $500,000 plan isn't for everyone. Even at a 6% return, that's $30,000 a year — not exactly luxury living, especially with rising medical costs, rent, and a grocery bill that seems to laugh at budgets.&nbsp;
Even with higher returns near 9%, you'd be working with about $45,000 a year — enough to get by, but probably not enough to quit your job unless your house is paid off, you have no debt, and you live a lean, frugal lifestyle. O'Leary did say it all comes down to <a href="https://www.benzinga.com/personal-finance/25/02/43539942/are-you-rich-heres-what-americans-think-you-need-to-be-considered-wealthy-2">your standard of living</a>, but for most people, living comfortably on that setup would require a serious commitment to keeping expenses low.
O'Leary's advice is simple, direct, and depending on your lifestyle…surprisingly doable. But his real point might be this: the path to financial freedom isn't always paved with millions. Sometimes, it's about knowing what you want, avoiding bad investments, and <a href="https://www.benzinga.com/personal-finance/25/02/43759618/charlie-munger-said-the-hardest-part-of-getting-rich-is-the-first-100000-but-from-there-it-snowballs-and-you-can-ease-off-the-gas">letting compound interest do the heavy lifting</a>.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Kevin O'Leary Says $500,000 Is The Magic Number To Live Comfortably — 'You Can Live Off Half A Million Bucks And Do Nothing Else To Make Money'

argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) has outperformed the market over the past 5 years by 18.91% on an annualized basis producing an average annual return of 32.94%. Currently, argenx has a market capitalization of $36.40 billion. 
Buying $1000 In ARGX: If an investor had bought $1000 of ARGX stock 5 years ago, it would be worth $4,066.85 today based on a price of $596.20 for ARGX at the time of writing.
<h3>argenx's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745008224_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARGX

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 36.99% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 23.33% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 20.10% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 16.33% at $0.98</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.74% at $0.67</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 7.69% at $5.60</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 4.92% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed up 4.74% at $52.17</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.66% at $1.54</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 4.43% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 4.24% at $1.26</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 3.85% at $0.91</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 3.70% at $1.40</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 3.45% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 3.39% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.39% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 3.38% at $0.46</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 3.21% at $4.44</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 73.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 46.39% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 10.63% at $0.57</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 7.19% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.17% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.91% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 4.68% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 4.67% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 4.60% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 3.75% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.72% at $6.03</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BBRRF

BLOZF

CLSH

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CXXIF

ELLXF

FFNTF

FUAPF

GRWG

GTBIF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

MRMD

NWVCF

OILFF

RMHB

SNDL

SOLCF

TGIFF

TLRY

UGRO

Marijuana Stock Movers For April 18, 2025

Press Releases

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Small Cap

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Contracts

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex to Participate at BIO Europe Spring 2025

CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

BETRF

CSDX

CSE:BETR

Aditxt

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Ensysce Biosciences

Entero Therapeutics

Galecto

GRI Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Onconetix

Organovo Holdings

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Synaptogenix

Tharimmune

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Genprex

Genprex (GNPX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL